Today, we are speaking with the one and only Robert Sapolsky, a Stanford neurobiologist, a MacArthur "Genius", and best-selling author of books exploring the nature of stress, social behavior, and — as he puts it — "the biology of the human predicament."

In his latest book, Determined, Sapolsky assertively lays out his vision of a world without free will — a world where as much as we feel like we're making decisions, the reality is that our choices are completely determined by biological and environmental factors outside of our control.

Before we get into it, it's worth saying that where this is heading, the reason to care about this question is that Sapolsky's argument has profound moral implications for our understanding of justice, personal responsibility, and whether any of us deserve to be judged or praised for our actions.

Mentioned on the Show

• Determined: A Science of Life Without Free Will (Sapolsky, 2023)
• Behave: The Biology of Humans at Our Best and Worst (Sapolsky, 2018 )
• A Primate's Memoir: A Neuroscientist's Unconventional Life Among the Baboons (Sapolsky, 2002)
• Free Agents: How Evolution Gave Us Free Will (Mitchell, 2023) 
• Sapolsky / Mitchell Debates – Part 1 (2023), Part 2 (2024)

Related Episodes

• Is addiction a disease? | Keith Humphreys
• Brain stimulation & "psychiatry 3.0" | Nolan Williams
• How we understand each other | Laura Gwilliams

Get in touch
We're doing some listener research and we want to hear from your neurons! Email us at at [email protected] if you'd be willing to help out, and we'll be in touch with some follow-up questions.

Episode Credits

This episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute. 

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Join us as we dive back into the world of psychedelic medicine with anesthesiologists Boris Heifets and Theresa Lii, who share intriguing new data that sheds light on how ketamine and placebo effects may interact in treating depression.

We explore provocative questions like: How much of ketamine's antidepressant effect comes from the drug itself versus the excitement of being in a psychedelics trial? What do we know about how placebo actually works in the brain? And should we view the placebo effect as a feature rather than a bug in psychiatric treatment?

Join us as we examine the complex interplay between psychoactive drugs, the brain's own opioid system, and the healing power of hope in mental health care.

Related research

• Preprint: Opioids Diminish the Placebo Antidepressant Response: A Post Hoc Analysis of a Randomized Controlled Ketamine Trial (medRxiv, 2024)
• Randomized trial of ketamine masked by surgical anesthesia in patients with depression (Nature Mental Health, 2023)
  
  

Related episodes

• Psychedelics, placebo, and anesthetic dreams | Boris Heifets (Part 1) 
• Psychedelics Inside Out: How do LSD and psilocybin alter perception? | Boris Heifets (Part 2)
• OCD and Ketamine | Carolyn Rodriguez
• Psychedelics and Empathy: Why are psychiatrists taking a fresh look at MDMA? | Rob Malenka

Related news

• Researchers find response to ketamine depends on opioid pathways, but varies by sex (Stanford Medicine, 2024)
• The rebirth of psychedelic medicine (Wu Tsai Neuro, 2023)
• Can Psychedelic Drugs Treat Physical Pain? (Scientific American, 2022)
• Scientists Say A Mind-Bending Rhythm In The Brain Can Act Like Ketamine (NPR, 2020)

Get in touch
We're doing some listener research and we want to hear from your neurons! Email us at at [email protected] if you'd be willing to help out, and we'll be in touch with some follow-up questions.

Episode Credits

This episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is host

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Today, we are going back into the archives for one of my favorite episodes: We are talking to neuroscientist, entrepreneur, and best-selling author, David Eagleman. We're talking about synaesthesia — and if you don't know what that is, you're about to find out.

Special Note
We are beyond thrilled that From Our Neurons to Yours has won a 2024 Signal Award in the Science Podcast category. It's a big honor — thanks to everyone who voted!

---

Imagine Thursday. Does Thursday have a color? What about the sound of rain — does that sound taste like chocolate? Or does the sound of a saxophone feel triangular to you? 

For about 3% of the population, the sharp lines between our senses blend together. Textures may have tastes, sounds, shapes, numbers may have colors. This sensory crosstalk is called synesthesia, and it's not a disorder, just a different way of experiencing the world. 

To learn about the neuroscience behind this fascinating phenomenon and what it tells us about how our brains perceive the world, we were fortunate enough to speak with David Eagleman, a neuroscientist, author, and entrepreneur here at Stanford who has long been fascinated by synesthesia and what it means about how our perceptions shape our reality.

Links

• Livewired (book)
• Incognito (book)
• Wednesday Is Indigo Blue (book)
• Neosensory (website)
• Synesthete.org (website)
• Inner Cosmos with David Eagleman (podcast)

Get in touch
We're doing some listener research and we want to hear from your neurons! Email us at at [email protected] if you'd be willing to help out, and we'll be in touch with some follow-up questions.

Episode Credits

This episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute. 

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Earlier this year, President Obama's signature BRAIN Initiative, which has powered advances in neuroscience for the past 10 years, had its budget slashed by 40%. 

Over the past decade, the BRAIN Initiative made roughly $4 billion in targeted investments in more than 1500 research projects across the country and has dramatically accelerated progress tackling fundamental challenges in neuroscience. As we head into the next federal budget cycle, the future of the initiative remains uncertain. 

Today we take stock of how the BRAIN Initiative transformed neuroscience over the past 10 years, and what the outlook is for the future of the field.

To give us an unparalleled behind the scenes view, we are fortunate to have Bill Newsome with us on the show. A world renowned expert in the brain mechanisms of visual perception and decision-making, Bill co-chaired the original BRAIN Initiative planning committee in 2013 (the same year he became the founding director of the Wu Tsai Neurosciences Institute here at Stanford). Don't miss this conversation!

Learn More

• About the BRAIN Initiative 
  • NIH BRAIN Initiative website
  • A Leader of Obama's New Brain Initiative Explains Why We Need It (WIRED, April 2013)
  • BRAIN @ 10: A decade of innovation (Neuron, Sept 2024)
  • Reflecting on a decade of BRAIN—10 Institutes and Centers, one mission (NIH BRAIN Blog, Aug 2024)
    
    
• About last year's funding cuts: 
  • Understanding the BRAIN Initiative budget (NIH BRAIN Initiative)
  • $278 million cut in BRAIN Initiative funding leaves neuroscientists in limbo (The Transmitter, April 2024)
  • The Future of BRAIN Initiative Funding Remains Unclear (The Transmitter, July 2024)

Get in touch
We're doing some listener research and we want to hear from your neurons! Email us at at [email protected] if you'd be willing to help out, and we'll be in touch with some follow-up questions.

Episode Credits

This episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute. 

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Given the widespread legalization of cannabis for medical and recreational uses, you'd think we'd have a better understanding of how it works. But ask a neuroscientist exactly how cannabinoid compounds like THC and CBD alter our perceptions or lead to potential medical benefits, and you'll soon learn just how little we know.

We know that these molecules hijack an ancient signaling system in the brain called the "endocannabinoid" system (translation: the "cannabinoids within"). These somewhat exotic signaling molecules (made of fatty lipids and traveling "backwards" compared to other transmitters) have been deeply mysterious until recently, when new tools made it possible to visualize their activity directly in the brain.

So what is the "day job" of the endocannabinoid system — and how does it connect to the dramatic highs that come with taking THC or the medical benefits of CBD? 

To unpack all this, we're talking this week with neuroscientist Ivan Soltesz, the James Doty Professor of Neurosurgery and Neuroscience at Stanford, and a leading expert on the endocannabinoid system.

Learn More

• The Soltesz Lab
• "Weeding out bad waves: towards selective cannabinoid circuit control in epilepsy" (Soltesz et al, Nature Reviews Neuroscience, 2015) 
• "Keep off the grass? Cannabis, cognition and addiction" (Parsons et al, Nature Reviews Neuroscience, 2016)
• "Marijuana-like brain substance calms seizures but increases aftereffects, study finds" (Goldman, Stanford Medicine News, 2021)
• "Retrograde endocannabinoid signaling at inhibitory synapses in vivo" (Dudok et al, Science, 2024)

Vote for us!
We are a finalist for a prestigious Signal Award for Best Science Podcast of 2024! Share your love for the show by voting for us in the Listener's Choice category by October 17. Thanks in advance!

Get in touch:
We're doing some listener research and we want to hear from your neurons! Email us at at [email protected] if you'd be willing to help out, and we'll be in touch with some follow-up questions.

Episode Credits

This episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute. 

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Today we are re-releasing an episode we did last year with Stanford neurobiologist Lisa Giocomo exploring the intersection of memory, navigation and the boundaries we create between ourselves and the world around us.

This episode was inspired by the idea of memory palaces. The idea is simple: Take a place you're very familiar with, say the house you grew up in, and place information you want to remember in different locations within that space. When it's time to remember those things, you can mentally walk through that space and retrieve those items.

This ancient technique reveals something very fundamental about how our brains work. It turns out that the same parts of the brain are responsible both for memory and for navigating through the world.

Scientists are learning more and more about these systems and the connections between them, and it's revealing surprising insights about how we build the narrative of our lives, how we turn our environments into an internal model of who we are, and where we fit into the world.

Join us to learn more about the neuroscience of space and memory.

Before we get into this week’s episode, we have a favor to ask. We're working to make this show even better, and we want to hear from you. We're in the process of gathering listener input and feedback. If you'd be willing to help out, send us a short note and we'll be in touch. As always, we are at [email protected]

Learn more:

• About Lisa Giocomo’s research
• About the story of Henry Molaison (patient H. M.), who lost the ability to form new memories after epilepsy treatment removed his hippocampus.
• About the 2014 Nobel Prize in medicine, awarded to John O’Keefe and to May-Britt and Edvard Moser (Giocomo’s mentors) for their discovery of the GPS system of the brain.
• About Memory Palaces, a technique used since ancient times to enhance memory using mental maps.

Episode Credits

This episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute. 

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

In the past few years, Big Pharma has released not one, but three new treatments for Alzheimer’s disease.

Aducanemab (2021), Lecanemab (2023), and Donanemab (2024), are the first treatments to effectively clear the brain of amyloid plaques — the sticky protein clumps whose build-up in the brain has defined the disease for decades. The problem? They may not help patients at all.

Today’s guest, Stanford neurologist Mike Greicius, considers the new amyloid-clearing drugs a major disappointment — and worse, says they likely do more harm than good for patients.

Despite this critique, Greicius, thinks that the next few years will be an exciting time for novel Alzheimer’s therapies, as growing biological understanding of Alzheimer’s risk and resilience bear fruit with promising new approaches to treatment.

Learn More:

Greicius is the Iqbal Farrukh and Asad Jamal Professor of Neurology and Neurological Sciences at Stanford Medicine, and a member of the Knight Initiative for Brain Resilience and Alzheimer's Disease Research Center at Stanford University.

Amyloid Drug Skepticism:

• Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies
  (Commentary, Journal of Alzheimer's Disease, 2024)
• New Drug Approved for Early Alzheimer’s (New York Times, 2024)
• Alzheimer's drug adoption in US slowed by doctors' skepticism (Reuters, 2024)
• One step back: Why the new Alzheimer’s plaque-attack drugs don’t work (Stanford Medicine Scope Blog, 2024)

Alzheimer's Genetics Research:

• Knight-funded research uncovers gene mutations that may prevent Alzheimer’s Disease (Knight Initiative for Brain Resilience, 2024)
• Why is a common gene variant bad for your brain? (Stanford Medicine Magazine, 2024)
• Scientists find genetic Alzheimer’s risk factor tied to African ancestry (Stanford Medicine, 2023)

Episode Credits

This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Getting help for depression can be like purgatory. Setting aside for a moment the stigma and other barriers to seeking treatment in the first place, finding the right combination of medication and/or therapy can be a months- or years-long process of trial and error. And for about one third of people, nothing seems to work.

Today we're talking with Dr. Leanne Williams, the founding director of the Stanford Center for Precision Mental Health and Wellness and Vincent V.C. Woo Professor in the Stanford Department of Psychiatry and Behavioral Sciences.

Williams and her team have recently used brain imaging and machine learning techniques to identify six distinct "biotypes" of depression — each of which may require a different approach to treatment. Beyond setting the stage for more targeted therapies, better understanding the biology behind the disease could finally cut through the stigma of one of the world's most common brain disorders.

Learn more

• Williams' Personalized and Translational Neuroscience Lab (PANlab)
• The Stanford Center for Precision Mental Health and Wellness
• NEW: Cognitive behavioral therapy enhances brain circuits to relieve depression (Stanford Medicine, 2024)
• Six distinct types of depression identified in Stanford Medicine-led study
  (Stanford Medicine, 2024)
  • Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety (Nature Medicine, 2024)
• Brain scans could help personalize treatment for people who are depressed or suicidal (Science, 2022)
• Williams' scientific publications
  
  

Episode Credits
This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Today, we're talking with Stanford neuro-oncologist, Michelle Monje. This is actually the third time we've had Michelle on the show, in part because she's been a pioneer of three exciting frontiers in neuroscience — so far! 

This week, we're going to talk about cancer neuroscience. Michelle founded this new field with her discovery that deadly brain tumors not only link up physically with the healthy brain tissue surrounding them, but the cancers actually need the brain's electrical activity to grow and spread.

It turns out that many cancers — not only in the brain — depend on nervous system innervation for their survival. Understanding this dependent relationship better may present an exciting new line of attack for oncology. 

Join us to learn more!

News coverage

• Brain tumors caused by normal neuron activity in mice predisposed to such tumors
• Brain tumors form synapses with healthy neurons, Stanford-led study finds
• Deadly brain cancers act like 'vampires' by hijacking normal cells to grow
• Engineered immune cells target broad range of pediatric solid tumors in mice

Relevant Publications

• Glioma synapses recruit mechanisms of adaptive plasticity
• Glioblastoma remodelling of human neural circuits decreases survival
• Electrical and synaptic integration of glioma into neural circuits
• Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma
• Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion

Review Articles

• The neuroscience of cancer
• Cancer hallmarks intersect with neuroscience in the tumor microenvironment
• Roadmap for the Emerging Field of Cancer Neuroscience

Episode Credits
This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

This week on From Our Neurons to Yours, we're talking about using new techniques for growing human brain tissue in the lab to solve a rare neurological disorder.

Host Nicholas Weiler sits down with Sergiu Pasca an innovative Stanford scientist who has developed groundbreaking technologies to grow human brain tissue in the lab, creating "organoids" and "assembloids" that model brain disorders like autism and schizophrenia. 

Pasca describes the process of turning patient skin cells into embryo-like stem cells and then into functional brain cells that can live and develop for over two years, and even be transplanted into rat brains to study their growth and development.

It may sound like science fiction, but these techniques represent a major step toward understanding and treating complex neurological conditions such as Timothy syndrome, a rare genetic disorder whose biology Pasca has spent the past 15 years unraveling. 

Join us for fascinating glimpse into the future of developmental neuroscience and  potential for new therapies for our remarkable self-assembling brains.

Learn more

• Brain organoids and assembloids are new models for elucidating, treating neurodevelopmental disorders | News Center | Stanford Medicine
• Impact of genes linked to neurodevelopmental diseases found | News Center | Stanford Medicine
• Scientists discover how dozens of genes may contribute to autism - The Washington Post
• Study suggests approach for treating rare disorder | National Institutes of Health (NIH)
• How lab-grown brain cells can now help us understand brain disorders

Episode Credits
This episode was produced by Michael Osborne, with production assistance by Morgan Honaker, and hosted by Nicholas Weiler. Art by Aimee Garza.

Send us a text!

Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.

Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.